UBS Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $89
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $87 to $89.
March 04, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Eliana Merle reaffirmed a Buy rating on Apellis Pharmaceuticals and increased the price target from $87 to $89.
The upgrade in the price target by a reputable analyst like Eliana Merle from UBS is a strong positive signal for Apellis Pharmaceuticals. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100